Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with TACE in GALNT14 Genotype-Guided HCC
NCT02504983Phase 4Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Aug 2015
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Complete Remission at 3 years. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02504983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504983.